Zobrazeno 1 - 10
of 38
pro vyhledávání: '"N. Yu Mironov"'
Autor:
M. A. Zelberg, N. Yu. Mironov, Kh. M. Dzaurova, Yu. A. Yuricheva, E. B. Maykov, P. S. Novikov, D. A. Gagloeva, M. A. Krimukova, S. F. Sokolov, S. P. Golitsyn
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 2, Pp 86-95 (2024)
Objective. Evaluate efficacy and safety of cavutilide (Refralon) for pharmacological cardioversion in patients with recurrent atrial fibrillation and flutter (AF/AFL), in 90days blanking period of catheter ablation.Materials and methods. included 56
Externí odkaz:
https://doaj.org/article/22ac86e42166436abe584631dc932ef7
Autor:
S. P. Golitsyn, M. V. Kostyukevich, L. Yu. Lajovic, N. Yu. Mironov, N. A. Mironova, M. D. Utsumueva, D. R. Khusyainova, N. B. Shlevkov, B. Ch. Bazarov, V. A. Azizov, E. D. Dzhishambaev, N. U. Zakirov, D. B. Goncharik
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 4, Pp 6-67 (2022)
The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any cont
Externí odkaz:
https://doaj.org/article/d7892ec6c7a64e76adb060b2723621cd
Autor:
D. A. Gagloeva, Kh. M. Dzaurova, M. A. Zelberg, N. Yu. Mironov, Yu. A. Yuricheva, S. F. Sokolov, M. A. Krymukova, A. I. Salpagarova, L. O. Dulaev, D. V. Pevzner, S. P. Golitsyn
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 22, Iss 4 (2023)
Aim. To compare the efficacy and safety of chemical cardioversion (CCV) with refralon and amiodarone in patients with paroxysmal atrial fibrillation and flutter (AF/AFL).Material and methods. Fifty five patients (mean age, 65±11 years) with paroxy
Externí odkaz:
https://doaj.org/article/9421170c3fc74df083e12f23e2bc4e63
Autor:
N. Yu. Mironov, Yu. A. Yuricheva, V. V. Vlodzyanovskiy, S. F. Sokolov, Kh. M. Dzaurova, S. P. Golitsyn, Yu. V. Shubik, M. V. Berman, M. M. Medvedev, A. E. Rivin, D. S. Parkhomchuk, A. E. Barybin, D. А. Balandin, R. E. Batalov, D. V. Terekhov, I. V. Evstifeev, I. R. Kildeev, O. V. Pyataeva, S. A. Zenin
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 5, Pp 668-673 (2021)
Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research cent
Externí odkaz:
https://doaj.org/article/fda3bc3bcec0409e89ef6af250af93a3
Autor:
N. Yu. Mironov, Yu. A. Yuricheva, V. V. Vlodzyanovskiy, S. F. Sokolov, Kh. M. Dzaurova, S. P. Golitsyn, Yu. V. Shubik, M. V. Berman, M. M. Medvedev, A. E. Rivin, D. S. Parkhomchuk, A. E. Barybin, D. А. Balandin, R. E. Batalov, D. S. Terekhov, I. V. Evstifeev, I. R. Kildeev, O. V. Pyataeva, S. A. Zenin
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 2, Pp 193-199 (2021)
Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research cent
Externí odkaz:
https://doaj.org/article/0f377f87549f4a628c7889891fa7039f
Autor:
S. P. Golitsyn, E. P. Panchenko, E. S. Kropacheva, L. Yu. Layovich, E. B. Maikov, N. Yu. Mironov, O. O. Shakhmatova
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 4, Pp 4-85 (2019)
Externí odkaz:
https://doaj.org/article/84663bffe54142379621feb27776db95
Ventricular arrhythmias. Ventricular tachycardias and sudden cardiac death. 2020 Clinical guidelines
Autor:
D. S. Lebedev, E. N. Mikhailov, N. M. Neminuschiy, E. Z. Golukhova, V. E. Babokin, V. V. Bereznitskaya, E. S. Vasichkina, S. V. Garkina, S. P. Golitsyn, K. V. Davtyan, D. V. Duplyakov, E. V. Zaklyazminskaya, S. A. Zenin, E. A. Ivanitsky, R. A-G. Ildarova, V. N. Komolyatova, A. A. Kostareva, E. A. Kuchinskaya, L. Yu. Lajovich (Nesterenko), V. K. Lebedeva, T. A. Lyubimtseva, L. M. Makarov, S. E. Mamchur, M. M. Medvedev, N. Yu. Mironov, L. B. Mitrofanova, S. V. Popov, A. Sh. Revishvili, F. G. Rzayev, A. B. Romanov, R. B. Tatarsky, S. A. Termosesov, M. D. Utsumueva, M. S. Kharlap, D. A. Tsaregorodtsev, M. A. Shkolnikova, N. B. Shlevkov, E. V. Shlyakhto, Yu. V. Shubik, S. M. Yashin
Publikováno v:
Российский кардиологический журнал, Vol 26, Iss 7 (2021)
Russian Society of Cardiology (RSC).With the participation of Russian Scientific Society of Clinical Electrophysiology, Arrhythmology and Cardiac Pacing, Russian Association of Pediatric Cardiologists, Society for Holter Monitoring and Noninvasive El
Externí odkaz:
https://doaj.org/article/7431fbdba5a4472bbfc0d3f4f39ea29f
Autor:
M. G. Arakelyan, L. A. Bockeria, E. Yu. Vasilieva, S. P. Golitsyn, E. Z. Golukhova, M. V. Gorev, K. V. Davtyan, O. M. Drapkina, E. S. Kropacheva, E. A. Kuchinskaya, L. Yu. Lajovich, N. Yu. Mironov, I. E. Mishina, E. P. Panchenko, A. Sh. Revishvili, F. G. Rzayev, B. A. Tatarsky, M. D. Utsumueva, O. O. Shakhmatova, N. B. Shlevkov, A. V. Shpektor, D. A. Andreev, E. A. Artyukhina, O. L. Barbarash, A. S. Galyavich, D. V. Duplyakov, S. A. Zenin, D. S. Lebedev, E. N. Mikhailov, N. A. Novikova, S. V. Popov, A. G. Filatov, E. V. Shlyakhto, Yu. V. Shubik
Publikováno v:
Российский кардиологический журнал, Vol 26, Iss 7 (2021)
Russian Society of Cardiology (RSC).With the participation of Russian Scientific Society of Clinical Electrophysiology, Arrhythmology and Cardiac Pacing, Russian Association of Cardiovascular Surgeons.Approved by the Scientific and Practical Council
Externí odkaz:
https://doaj.org/article/bec19ff68992493eb9e972f8b2328631
Autor:
N. Yu. Mironov, V. V. Vlodzyanovskiy, Yu. A. Yuricheva, S. F. Sokolov, S. P. Golitsyn, L. V. Rosenstraukh, E. I. Chazov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 14, Iss 6, Pp 826-830 (2019)
Aim. To compare safety of new class III antiarrhythmic drug Refralon with direct current cardioversion (DCC) in patients with persistent atrial fibrillation (AF). Material and methods. 60 patients with persistent AF were randomized to groups of DCC (
Externí odkaz:
https://doaj.org/article/f47249aaf92d44f9aa129d5064c2d1e0
Autor:
N. Yu. Mironov, V. V. Vlodzyanovskiy, Yu. A. Yuricheva, S. F. Sokolov, S. P. Golitsyn, L. V. Rosenstraukh, E. I. Chazov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 14, Iss 5, Pp 664-669 (2018)
Aim. We aimed to compare effectiveness of new class III antiarrhythmic drug Refralon with direct current cardioversion (DCC) in patients with persistent atrial fibrillation (AF).Material and methods. 60 patients with persistent AF were randomized to
Externí odkaz:
https://doaj.org/article/0ac2b7081f3446bc854ffbc0cfffd425